Want to see LGVN full AI Analyst Report?
LGVN Stock Chart & Stats
$0.68
>-$0.01(-1.19%)
At close: 4:00 PM EDT
$0.68
>-$0.01(-1.19%)
Day’s Range― - ―
52-Week Range$4.76 - $12.30
Previous CloseN/A
Volume160.25K
Average Volume (3M)59.31K
Market Cap
$30.32M
Enterprise Value$12.56
Total Cash (Recent Filing)$10.08M
Total Debt (Recent Filing)$581.00K
Price to Earnings (P/E)―
Beta0.89
Next Earnings
Nov 06, 2026EPS Estimate
-1.63Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-10.10
Shares Outstanding3,043,297
10 Day Avg. Volume93,695
30 Day Avg. Volume59,306
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)1.57
Price to Sales (P/S)7.42
P/FCF Ratio-0.47
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$3.00Price Target Upside341.18% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-7.2
Revenue Forecast (FY)$1.54M
Bulls Say, Bears Say
Bulls Say
Regulatory And Intellectual-property SupportThe broad patent estate and expedited FDA designations can protect differentiation, support faster regulatory engagement and improve partnering prospects across multiple high-need regenerative medicine indications.
Diversified Clinical PipelineMultiple indications give the lead cell therapy several potential development paths, reducing reliance on a single disease area and increasing the opportunity to leverage one platform across pediatric and aging-related markets.
Low Leverage And Regulatory ProgressLimited debt reduces fixed financial obligations, while the effective PDCM IND advances another program toward registrational development. Together, these factors preserve strategic flexibility despite the company’s funding needs.
Bears Say
Persistent Cash Burn And Limited RunwaySustained cash consumption means Longeveron must secure financing, partnerships or other capital to continue development. This creates ongoing funding risk and could constrain trial execution or commercialization investment.
Minimal Revenue And Widening LossesThe company lacks a recurring commercial revenue base and its losses are increasing as clinical spending continues. Without successful late-stage development and eventual commercialization, operating scale and profitability remain distant.
High Dependence On Clinical OutcomesA pivotal Phase 2b readout is central to validating laromestrocel’s efficacy and advancing a potential BLA pathway. An inconclusive result or difficult regulatory feedback could materially delay development and weaken partnership prospects.
Longeveron News
LGVN FAQ
What was Longeveron’s price range in the past 12 months?
Longeveron lowest stock price was $4.76 and its highest was $12.30 in the past 12 months.
What is Longeveron’s market cap?
Longeveron’s market cap is $30.32M.
When is Longeveron’s upcoming earnings report date?
Longeveron’s upcoming earnings report date is Nov 06, 2026 which is in 64 days.
How were Longeveron’s earnings last quarter?
Longeveron released its earnings results on Aug 12, 2026. The company reported -$1.9 earnings per share for the quarter, missing the consensus estimate of -$1.75 by -$0.15.
Is Longeveron overvalued?
According to Wall Street analysts Longeveron’s price is currently Undervalued.
Does Longeveron pay dividends?
Longeveron does not currently pay dividends.
What is Longeveron’s EPS estimate?
Longeveron’s EPS estimate is -1.63.
How many shares outstanding does Longeveron have?
Longeveron has 3,043,297 shares outstanding.
What happened to Longeveron’s price movement after its last earnings report?
Longeveron reported an EPS of -$1.9 in its last earnings report, missing expectations of -$1.75. Following the earnings report the stock price went down -6.601%.
Which hedge fund is a major shareholder of Longeveron?
Currently, no hedge funds are holding shares in LGVN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Longeveron Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$3.00 (341.18% Upside)
$3.00 (341.18% Upside)
Blogger Sentiment
Bearish
LGVN Sentiment 100%
Sector Average ―
Sector Average ―
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 2.2%
Last 30 Days ▼ 2.2%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-17.50%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-7.53%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Longeveron
Longeveron Inc. is a biotechnology company currently in the clinical development stage, dedicated to pioneering cell-based therapies. These treatments are designed to address both age-related conditions and various critical, life-threatening illnesses. The company's primary investigational product is LOMECEL-B, a sophisticated cellular therapy. This product is created from medicinal signaling cells that are cultivated and expanded after being harvested from the bone marrow of healthy young adult donors. Longeveron is actively conducting Phase 1 and Phase 2 clinical trials to evaluate LOMECEL-B's potential across a diverse range of indications. These include age-related frailty, Alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome (ARDS), and hypoplastic left heart syndrome (HLHS). Established in 2014, Longeveron Inc. operates from its headquarters in Miami, Florida.
LGVN Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call balanced meaningful scientific, regulatory, and validation milestones (upcoming ELPIS II readout, XPRIZE finalist award, high-profile publications, strong IP and expedited designations, and regulatory progress for PDCM) against material financial constraints (very low revenues, rising expenses, widening net loss, and a cash runway into Q4 2026). The business outlook is highly dependent on the imminent trial readout and the company's ability to secure partnerships or financing to extend the runway and commercialize programs.View all LGVN earnings summariesLGVN Stock 12 Month Forecast
Average Price Target
$3.00
▲(341.18% Upside)
Technical Analysis
Ibio
―
Edesa Biotech
―
Chemomab Therapeutics
―
Processa Pharmaceuticals
―
FibroBiologics, Inc.
―
Ownership Overview
20.12% Insiders
2.17% Mutual Funds
― Other Institutional Investors
75.80% Public Companies and
Individual Investors